Literature DB >> 18608096

Muscle histopathology in upper motor neuron-dominant amyotrophic lateral sclerosis.

Gianni Sorarù1, Carla D'Ascenzo, Piero Nicolao, Marco Volpe, Sara Martignago, Arianna Palmieri, Vincenzo Romeo, Konstantinos Koutsikos, Francesco Piccione, Valentina Cima, Elena Pegoraro, Corrado Angelini.   

Abstract

The distinction between primary lateral sclerosis (PLS) and amyotrophic lateral sclerosis (ALS) still remains debated. Recently, PLS patients displaying lower motor neuron (LMN) signs have been defined as 'upper motor neuron (UMN)-dominant ALS', using 'clinically pure PLS' diagnosis to those with no LMN signs. To further characterize the LMN involvement in UMN-dominant ALS we investigated the presence and the extent of neurogenic abnormalities in the skeletal muscle of patients affected with a pyramidal syndrome consistent with UMN-dominant ALS. A total of nine patients affected with UMN-dominant ALS were analysed. In all cases, muscle biopsies showed the presence of scattered or clustered atrophic angulated fibres in small groups, and a mild to moderate fibre type-grouping. Target and targetoid fibres were detected in two cases only. Three patients had a second muscle biopsy which demonstrated a roughly unchanged pattern of chronic denervation with still moderate reinnervation phenomena. This study suggests that in UMN-dominant ALS muscle denervation may be characterized by an early chronic impairment of a restricted number of LMNs. The extent rather than the presence of LMN signs may allow to categorize patients with motor neuron disease involving mainly UMN into distinct entities.

Entities:  

Mesh:

Year:  2008        PMID: 18608096     DOI: 10.1080/17482960802206801

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler        ISSN: 1471-180X


  4 in total

Review 1.  Muscle biopsy evaluation in neuromuscular disorders.

Authors:  Nanette C Joyce; Björn Oskarsson; Lee-Way Jin
Journal:  Phys Med Rehabil Clin N Am       Date:  2012-08       Impact factor: 1.784

2.  Characterization of intercostal muscle pathology in canine degenerative myelopathy: a disease model for amyotrophic lateral sclerosis.

Authors:  Brandie R Morgan; Joan R Coates; Gayle C Johnson; Alyssa C Bujnak; Martin L Katz
Journal:  J Neurosci Res       Date:  2013-09-16       Impact factor: 4.164

Review 3.  Targeted Molecular Therapies for SBMA.

Authors:  Carlo Rinaldi; Bilal Malik; Linda Greensmith
Journal:  J Mol Neurosci       Date:  2015-11-17       Impact factor: 3.444

4.  A comprehensive assessment of the SOD1G93A low-copy transgenic mouse, which models human amyotrophic lateral sclerosis.

Authors:  Abraham Acevedo-Arozena; Bernadett Kalmar; Shafa Essa; Thomas Ricketts; Peter Joyce; Rosie Kent; Claire Rowe; Andy Parker; Anna Gray; Majid Hafezparast; Julian R Thorpe; Linda Greensmith; Elizabeth M C Fisher
Journal:  Dis Model Mech       Date:  2011-05-02       Impact factor: 5.758

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.